Eli Lilly has unveiled plans to expand its long-standing partnership with Purdue University, with the drugmaker investing up ...

Novo Nordisk and Septerna have announced a new partnership worth $2.2bn to develop oral small molecule drugs for type 2 ...

GSK will gain access to efimosfermin by acquiring Boston’s subsidiary BP Asset IX for $1.2bn upfront and up to $800m in ...

New McKinsey and Gartner data show that organisations who regularly reset strategy can outperform peers by up to 60%. In fast ...

Madrigal Pharmaceuticals’ Rezdiffra (resmetirom) has demonstrated sustained efficacy in a late-stage trial of patients with ...

Cytokinetics has shared positive top-line results from a late-stage study of its investigational oral cardiac myosin ...

Pharma marketers are embracing chat-based tools to engage HCPs and patients faster, simplify PI sharing, and gain real-time ...

Eli Lilly has announced that its Zepbound (tirzepatide) was superior to Novo Nordisk’s Wegovy (semaglutide) across all weight ...

The phase 3 GLISTEN trial has been evaluating the candidate in adults with PBC and cholestatic pruritus, or relentless itch, ...

Johnson & Johnson (J&J) has announced that its bladder cancer therapy Balversa (erdafitinib) has been accepted by the ...

Roche’s Perjeta (pertuzumab)-based regimen has demonstrated sustained survival benefits in patients with early-stage breast ...

We can’t talk about challenges to women’s reproductive health without acknowledging that we’re living in unprecedented times, ...